Abstract
The bone is a dynamic tissue that is continuously removed and replaced (i.e., remodeled) in order to (1) ensure adaptation of the skeleton to weight-bearing (shape is function), (2) repair microdamages (cracks) that result from mechanical stresses, and (3) allow for mobilization of calcium from the skeleton in order to maintain serum calcium homeostasis. Bone remodeling is initiated by the development and activation of osteoclasts, the bone-resorbing cell, which then release growth factors capable to activate osteoblasts, the bone-forming cell. The activities of bone removal and deposition are therefore coupled within each “bone multicellular unit” or BMU. After the completion of growth, the bone size and mineral content have reached its peak and will be maintained more or less unchanged during the adult life in absence of pathophysiological conditions thanks to moderate levels of bone remodeling that are perfectly balanced between resorption and formation within each BMU. In addition, the skeleton continuously responds to mechanical stimuli resulting from both muscle contraction and weight-bearing, by directly stimulating bone formation (i.e., without prior resorption), a process known as bone modeling. This process in particular is responsible for the increased bone diameter and bone mass observed in physically active individuals, furthermore in athletes. It is controlled by osteocytes, which are terminally differentiated osteoblasts that have lost their capacity to form new bone but are entrenched in the bone and form a dense network of “sensing” cells capable to respond to mechanical stimuli, as well as to microdamages, and control both modeling and local remodeling processes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci. 2006;1092:385–96.
Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26(2):229–38.
Seeman E, Delmas PD. Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354(21):2250–61.
Zebaze RM, Ghasem-Zadeh A, Bohte A, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2010;375(9727):1729–36.
Farr JN, Fraser DG, Wang H, et al. Identification of senescent cells in the bone microenvironment. J Bone Miner Res. 2016;31(11):1920–9.
Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148(6):2635–43.
Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008;29(2):155–92.
Bruzzaniti A, Baron R. Molecular regulation of osteoclast activity. Rev Endocr Metab Disord. 2006;7(1–2):123–39.
Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19.
Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003;111(8):1221–30.
Ma YL, Cain RL, Halladay DL, et al. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology. 2001;142(9):4047–54.
Heino TJ, Hentunen TA. Differentiation of osteoblasts and osteocytes from mesenchymal stem cells. Curr Stem Cell Res Ther. 2008;3(2):131–45.
Murshed M, Harmey D, Millan JL, McKee MD, Karsenty G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev. 2005;19(9):1093–104.
Seeman E. Loading and bone fragility. J Bone Miner Metab. 2005;23(Suppl):23–9.
Duque G. Bone and fat connection in aging bone. Curr Opin Rheumatol. 2008;20(4):429–34.
Bonjour JP, Schurch MA, Chevalley T, Ammann P, Rizzoli R. Protein intake, IGF-1 and osteoporosis. Osteoporos Int. 1997;7(3):S36–42.
Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107(4):513–23.
Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577–89.
Staehling-Hampton K, Proll S, Paeper BW, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002;110(2):144–52.
van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004;199(6):805–14.
Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19(13):1842–4.
Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146(11):4577–83.
Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005;37(2):148–58.
Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012;33:747.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ferrari, S.L. (2019). Pathophysiology of Osteoporosis. In: Ferrari, S., Roux, C. (eds) Pocket Reference to Osteoporosis. Springer, Cham. https://doi.org/10.1007/978-3-319-26757-9_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-26757-9_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-26755-5
Online ISBN: 978-3-319-26757-9
eBook Packages: MedicineMedicine (R0)